In Memoriam: Heloisa Sabin

WASHINGTON, D.C. – October 17, 2016 – The Sabin Vaccine Institute joins a global community of friends, partners and global health advocates in celebrating the life of Heloisa Sabin (née Dunshee de Abranches) who passed away October 12 at the age of 98. Wife of the late Dr. Albert B. Sabin, who developed the oral live virus polio vaccine, Heloisa Sabin shared her late husband’s dedication to the elimination of needless human suffering and poverty.

The International Association of Immunization Managers Holds Inaugural Joint Regional Meeting in Beijing

Beijing, China — September 22, 2016 — The International Association of Immunization Managers (IAIM), based at the Sabin Vaccine Institute (Sabin), today began its first-ever regional meeting for members from Asia and the Pacific in Beijing, China.

Experts Gather to Honor a Decade of Progress to End Child Deaths from Rotavirus

Melbourne, Australia — September 7, 2016 — Beginning today, the 12th International Rotavirus Symposium will bring together hundreds of stakeholders from over 50 countries to provide an update on new data and research that will inform public health agendas related to prevention of rotavirus gastroenteritis, the leading cause of severe diarrhea in children worldwide.

Experts in Dengue Control Form New Alliance to Bridge Vaccine and Vector Approaches and Expand Efforts to Zika and other Aedes-Transmitted Diseases

Mexico City, Mexico – August 31, 2016 – Today, four leading institutions at the forefront of dengue prevention and control—the International Vaccine Institute (IVI), the International Vaccine Access Center (IVAC) of the Johns Hopkins University, the Partnership for Dengue Control Foundation (PDC) and the Sabin Vaccine Institute—announced a new global alliance to integrate approaches to fight dengue and other Aedes-transmitted diseases under one strategic umbrella. Named the Global Dengue and Aedes-transmitted Diseases Consortium (GDAC), this new partnership will expand its expertise in dengue to other Aedes-transmitted diseases including Zika, chikungunya and yellow fever, responding to the urgent need for coordination in the currently fragmented efforts to control the diseases transmitted by one of the world's most dangerous animals—the Aedes mosquito.

Sabin Vaccine Institute Awarded Funding to Advance Country Ownership of Immunization

WASHINGTON, D.C. — August 25, 2016 — The Sabin Vaccine Institute announced today that it has received an award of US$468,328 from the U.S. Centers for Disease Control and Prevention (CDC) to support initiatives to improve sustainable immunization financing. The project, conducted in partnership with the Pan American Health Organization (PAHO), will support sustainable financing, planning and decision-making for immunization programs in low- and middle-income countries. The program will launch in the Democratic Republic of Congo, Senegal and Kenya in 2016.

Countries Showcase Innovations for Sustainable Funding of Immunization at Kathmandu Conference

KATHMANDU, NEPAL — July 19, 2016 — The Sabin Vaccine Institute’s Sustainable Immunization Financing (SIF) Program today assembled senior officials from 21 countries to share their successes in increasing government budget allocations for national immunization programs. Greater political commitment and advocacy are building the momentum needed for countries to fully finance their immunization programs by 2020 and achieve the goals set forth in the Global Vaccine Action Plan (GVAP).

Sabin Vaccine Institute Partners with King Saud University to Build Vaccine Research and Development Capacity in Saudi Arabia

WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.